With oncology growth rates on the rise, pharma companies are pressured to develop and manufacture life-saving therapies with speed and agility. Cancer growth rates are driven by environmental factors, lifestyle choices, and an aging population. Approximately 42% of the oncology market pipeline is attributed to oral solid doses.* Since oncology drugs are commonly categorized as highly potent, they require various handling and safety strategies.
In this webinar, toxicologist Joe Galati discusses:
- Criteria for evaluating highly potent small molecules
- Toxicity banding systems
- Downgrading a molecule from high potent to low potent:
- Safety and handling strategies
*Source: IQVIA- Global MIDAS Edition Includes antineoplastic agents (L01) and endocrine therapy (L02)- 248 molecules, OSD includes: tablets, ODT, capsules